These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
117 related items for PubMed ID: 9299261
1. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Gynecol Oncol; 1997 Sep; 66(3):454-63. PubMed ID: 9299261 [Abstract] [Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Forum (Genova); 2000 Sep; 10(4):323-32. PubMed ID: 11535983 [Abstract] [Full Text] [Related]
8. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Mouratidou D, Gennatas C, Michalaki V, Papadimitriou A, Andreadis CH, Sykiotis C, Tsavaris N. Anticancer Res; 2007 Sep; 27(1B):681-5. PubMed ID: 17348460 [Abstract] [Full Text] [Related]
9. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol; 2006 Feb 01; 24(4):579-86. PubMed ID: 16446330 [Abstract] [Full Text] [Related]
13. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E, AGO-OVAR, GINECO. J Natl Cancer Inst; 2006 Aug 02; 98(15):1036-45. PubMed ID: 16882940 [Abstract] [Full Text] [Related]
14. The pharmacoeconomics of cancer therapies. Bishop JF, Macarounas-Kirchman K. Semin Oncol; 1997 Dec 02; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279 [Abstract] [Full Text] [Related]
16. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M, GRACES Clinical Trial Consortium. Gynecol Oncol; 2008 May 02; 109(2):174-81. PubMed ID: 18314182 [Abstract] [Full Text] [Related]
18. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation]. Gao KF, Liu FY, Chen FJ, Feng YL. Ai Zheng; 2007 Apr 02; 26(4):431-4. PubMed ID: 17430668 [Abstract] [Full Text] [Related]